Navigation Links
MAP Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Date:1/4/2012

MOUNTAIN VIEW, Calif., Jan. 4, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2012 at 10:00 a.m. PT in San Francisco.

A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay also will be available within 24 hours for seven days following each presentation.

About MAP Pharmaceuticals

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. The New Drug Application for LEVADEX is currently under review by the U.S. Food and Drug Administration. MAP Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

    CONTACT:

    Lisa Borland

    MAP Pharmaceuticals, Inc.

    650-386-3122

    lborland@mappharma.com


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Jazz Pharmaceuticals to Hold Investor Conference Call on January 5 to Discuss 2012 Financial Guidance and Azur Pharma Transaction
2. Radient Pharmaceuticals Announces Reverse Stock Split
3. Idenix Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
4. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
5. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
6. Endo Pharmaceuticals to Present at J.P. Morgan 30th Annual Healthcare Conference
7. Provenance Biopharmaceuticals Corp. Announces $8M Financing Arrangement
8. Valeant Pharmaceuticals Completes Acquisition of iNova
9. Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires
10. Valeant Pharmaceuticals to Hold Conference Call to Announce 2012 Financial Guidance
11. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... of Jerusalem announced today that it had signed ... BioTheryX, Inc. , developer of novel protein degradation and ... development and commercialization of drug candidates representing first-in-class therapy ... license were not disclosed. The novel technology ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Myeloid Leukemia Market ... to their offering.       (Logo: ... Myeloid Leukemia Market and Competitive Landscape Highlights ... Leukemia pipeline products, Acute Myeloid Leukemia epidemiology, ...
(Date:5/3/2016)... 2016 Research and Markets has ... Cell Therapy Market Outlook 2020" report to their ... , ,Recombinant technology has improved significantly in past years ... developed in coming years. Many cancer drugs have been ... therapies are also expected to be developed with its ...
Breaking Medicine Technology:
(Date:5/6/2016)... , ... May 06, 2016 , ... ... arrival of Sovaldi, which made headlines mostly for its cost despite its potential ... and moral questions surrounding the drug—part of a class called direct-acting antivirals (DAAs)—have ...
(Date:5/6/2016)... ... 2016 , ... RowdMap, Inc. co-founder, Joshua Rosenthal, PhD, joins ... Deputy Administrator at Centers for Medicare and Medicaid Services (CMS); Ali Khan, MD, ... Officer at Health Care Service Corporation (Blue Cross and Blue Shield of Illinois, ...
(Date:5/5/2016)... Texas (PRWEB) , ... May 05, 2016 , ... ... the Responsible Wool Standard (RWS) for public stakeholder review. The stakeholder review is an ... that it meets its goals and delivers value to the wool industry., The RWS ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... This weekend, from Friday, May 6 - ... on steep California terrain at the first Team Semper Fi Mountain Bike Camp, hosted in ... will be mountain bike legends Mark Weir and Jason Moeschler, who’ll share pro tips with ...
(Date:5/5/2016)... Indianapolis, IN (PRWEB) , ... May 05, 2016 ... ... employee benefits advisory organization, announces McLaughlin & Smoak Benefits as the latest addition ... & Smoak Benefits has a dedicated team of compliance, wellness, human resources, and ...
Breaking Medicine News(10 mins):